Literature DB >> 22814953

Differential proliferative index of cancer stem-like cells in primary and recurrent medulloblastoma in human.

Xuqun Tang1, Yu Yao, Jingjing Zhu, Kunlin Jin, Yin Wang, Ying Mao, Liangfu Zhou.   

Abstract

PURPOSE: Medulloblastoma is the most common malignant primitive neuroectodermal tumor found in children. It has a tendency to recur at a primary or distant site. The mechanism underlying the regulation of the recurrence of medulloblastoma remains largely unknown. Recently, several reports have described that cancer stem-like cells (CSCs) can be identified and isolated in medulloblastoma. The authors therefore attempted to demonstrate the correlation between the biological features of medulloblastoma's CSCs and its recurrence.
METHODS: The data used were obtained in five consecutive patients with medulloblastomas who subsequently experienced tumor recurrence from 2004 to 2007. The authors performed the immunohistochemical assays to analyze the expression of CSC markers, proliferation features, and proliferative status of CSCs in primary and recurrent medulloblastoma.
RESULTS: Of the five patients, two had recurrence at the primary site and three had a distant recurrence. CSC markers such as CD133(Prominin-1), DCX, PSA-NCAM, TUC-4, and nestin were expressed regardless of primary or recurrent medulloblastoma. All the five tumor specimens had a high proliferation index (PI). The PI was even higher in the group of patients after recurrence at a distant site (p<0.05), while the PI remained almost the same after primary recurrence. The Ki67/nestin-, Ki67/DCX-, and Ki67/TUC-4-positive cells were significantly increased in recurrent medulloblastoma at both the primary and distant sites, whereas CSCs in primary medulloblastoma showed much lower proliferative features (p<0.05).
CONCLUSIONS: Our data suggest that tumorigenesis of medulloblastomas and their recurrence might be related to CSCs. More proliferating CSCs in medulloblastomas denote worse prognosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22814953     DOI: 10.1007/s00381-012-1856-z

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  24 in total

1.  Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study.

Authors:  M D Ris; R Packer; J Goldwein; D Jones-Wallace; J M Boyett
Journal:  J Clin Oncol       Date:  2001-08-01       Impact factor: 44.544

2.  Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.

Authors:  Anastasia Murat; Eugenia Migliavacca; Thierry Gorlia; Wanyu L Lambiv; Tal Shay; Marie-France Hamou; Nicolas de Tribolet; Luca Regli; Wolfgang Wick; Mathilde C M Kouwenhoven; Johannes A Hainfellner; Frank L Heppner; Pierre-Yves Dietrich; Yitzhak Zimmer; J Gregory Cairncross; Robert-Charles Janzer; Eytan Domany; Mauro Delorenzi; Roger Stupp; Monika E Hegi
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

3.  Tumor environment dictates medulloblastoma cancer stem cell expression and invasive phenotype.

Authors:  Borhane Annabi; Shanti Rojas-Sutterlin; Carl Laflamme; Marie-Paule Lachambre; Yannève Rolland; Hervé Sartelet; Richard Béliveau
Journal:  Mol Cancer Res       Date:  2008-06       Impact factor: 5.852

4.  Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.

Authors:  Roberto Pallini; Lucia Ricci-Vitiani; Giuseppe Luigi Banna; Michele Signore; Dario Lombardi; Matilde Todaro; Giorgio Stassi; Maurizio Martini; Giulio Maira; Luigi Maria Larocca; Ruggero De Maria
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

Review 5.  Prognostic factors in medulloblastoma.

Authors:  M T Giordana; P Schiffer; D Schiffer
Journal:  Childs Nerv Syst       Date:  1998-06       Impact factor: 1.475

6.  B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells.

Authors:  Yu Yao; Xiaomei Wang; Kunlin Jin; Jianhong Zhu; Yin Wang; Sidong Xiong; Ying Mao; Liangfu Zhou
Journal:  J Neurooncol       Date:  2008-05-14       Impact factor: 4.130

7.  Stem cell marker CD133 affects clinical outcome in glioma patients.

Authors:  Felix Zeppernick; Rezvan Ahmadi; Benito Campos; Christine Dictus; Burkhard M Helmke; Natalia Becker; Peter Lichter; Andreas Unterberg; Bernhard Radlwimmer; Christel C Herold-Mende
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

8.  CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors.

Authors:  Dagmar Beier; Jörg Wischhusen; Wolfgang Dietmaier; Peter Hau; Martin Proescholdt; Alexander Brawanski; Ulrich Bogdahn; Christoph P Beier
Journal:  Brain Pathol       Date:  2008-03-26       Impact factor: 6.508

9.  Immunohistochemical markers for prognosis of average-risk pediatric medulloblastomas. The effect of apoptotic index, TrkC, and c-myc expression.

Authors:  Andrey Korshunov; Marina Savostikova; Sergey Ozerov
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

Review 10.  Brain tumor stem cells: view from cell proliferation.

Authors:  Yu Yao; Xuqun Tang; Shiqi Li; Ying Mao; Liangfu Zhou
Journal:  Surg Neurol       Date:  2009-03
View more
  6 in total

1.  Salinomycin Suppresses PDGFRβ, MYC, and Notch Signaling in Human Medulloblastoma.

Authors:  Shuang Zhou; Fengfei Wang; Ying Zhang; Max R Johnson; Steven Qian; Min Wu; Erxi Wu
Journal:  Austin J Pharmacol Ther       Date:  2014

2.  Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression.

Authors:  Jamie Zagozewski; Stephanie Borlase; Brent J Guppy; Ludivine Coudière-Morrison; Ghazaleh M Shahriary; Victor Gordon; Lisa Liang; Stephen Cheng; Christopher J Porter; Rhonda Kelley; Cynthia Hawkins; Jennifer A Chan; Yan Liang; Jingjing Gong; Carolina Nör; Olivier Saulnier; Robert J Wechsler-Reya; Vijay Ramaswamy; Tamra E Werbowetski-Ogilvie
Journal:  Commun Biol       Date:  2022-07-14

3.  Intrabodies against the Polysialyltransferases ST8SiaII and ST8SiaIV inhibit Polysialylation of NCAM in rhabdomyosarcoma tumor cells.

Authors:  Stefan Somplatzki; Martina Mühlenhoff; Andrea Kröger; Rita Gerardy-Schahn; Thomas Böldicke
Journal:  BMC Biotechnol       Date:  2017-05-12       Impact factor: 2.563

Review 4.  Metabolic determinants of stemness in medulloblastoma.

Authors:  Paula Martín-Rubio; Pilar Espiau-Romera; Alba Royo-García; Laia Caja; Patricia Sancho
Journal:  World J Stem Cells       Date:  2022-08-26       Impact factor: 5.247

5.  Ki67 Proliferation Index as a Histopathological Predictive and Prognostic Parameter of Oral Mucosal Melanoma in Patients without Distant Metastases.

Authors:  Xuhui Ma; Yunteng Wu; Tian Zhang; Hao Song; Houyu Jv; Wei Guo; Guoxin Ren
Journal:  J Cancer       Date:  2017-10-17       Impact factor: 4.207

6.  Human Medulloblastoma Cell Lines: Investigating on Cancer Stem Cell-Like Phenotype.

Authors:  Arianna Casciati; Mirella Tanori; Rémi Manczak; Sofiane Saada; Barbara Tanno; Paola Giardullo; Elena Porcù; Elena Rampazzo; Luca Persano; Giampietro Viola; Claire Dalmay; Fabrice Lalloué; Arnaud Pothier; Caterina Merla; Mariateresa Mancuso
Journal:  Cancers (Basel)       Date:  2020-01-17       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.